Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2325-2340

  Deblon, N ^a   Bourgoin, L ^a   Veyrat Durebex, C ^a   Peyrou, M ^a   Vinciguerra, M ^a   Caillon, A ^a   Maeder, C ^a   Fournier, M ^a   Montet, X ^a   Rohner Jeanrenaud, F ^a   Foti, M ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

diabetes; euglycaemic hyperinsulinaemic clamps; GLUT; insulin resistance; IRS; mTOR; PTEN; rapamycin; Sirolimus; skeletal muscle

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BODY FAT; BODY MASS; CELL MEMBRANE; CLAMP; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; METABOLIC PARAMETERS; MUSCLE INJURY; MYOTUBE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; TREATMENT DURATION; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; CELLS, CULTURED; DIET, HIGH-FAT; FATTY LIVER; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 4; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; WEIGHT LOSS;

EID: 84858272602     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01716.x     Document Type: Article

References (57)

1. Ansermot N, Fathi M, Veuthey JL, Desmeules J, Rudaz S, Hochstrasser D, (2008). Simultaneous quantification of cyclosporine, tacrolimus, sirolimus and everolimus in whole blood by liquid chromatography-electrospray mass spectrometry. Clin Biochem 41: 728-735.
2. Bell E, Cao X, Moibi JA, Greene SR, Young R, Trucco M, et al,. (2003). Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52: 2731-2739. (Pubitemid 37339702)
3. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS, (2006). The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 49: 2341-2349. (Pubitemid 44359095)
4. Chakrabarti P, English T, Shi J, Smas CM, Kandror KV, (2010). Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes 59: 775-781.
5. Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, Hsu HM, et al,. (2009). Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clin Pharmacol Toxicol 105: 188-198.
6. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P, (2007). mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450: 736-740. (Pubitemid 350207689)
7. Cybulski N, Polak P, Auwerx J, Ruegg MA, Hall MN, (2009). mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci U S A 106: 9902-9907.
8. Dancey J, (2010). mTOR signaling and drug development in cancer. Nat Rev. Clin Oncol 7: 209-219.
9. Dann SG, Selvaraj A, Thomas G, (2007). mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 13: 252-259. (Pubitemid 46836871)
10. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, et al,. (2008). mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57: 945-957.
11. French DC, Saltzgueber M, Hicks DR, Cowper AL, Holt DW, (2001). HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin Chem 47: 1316-1319. (Pubitemid 32579126)
12. Gutierrez-Dalmau A, Campistol JM, (2007). Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 67: 1167-1198. (Pubitemid 46871026)
13. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ, (1965). Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25: 1375-1384.
14. Hoehn KL, Hohnen-Behrens C, Cederberg A, Wu LE, Turner N, Yuasa T, et al,. (2008). IRS1-independent defects define major nodes of insulin resistance. Cell Metab 7: 421-433. (Pubitemid 351598028)
15. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, et al,. (2010). Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59: 1338-1348.
16. Huang D, Cheung AT, Parsons JT, Bryer-Ash M, (2002). Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes. J Biol Chem 277: 18151-18160. (Pubitemid 34967631)
17. Ishikura S, Antonescu CN, Klip A, (2010). Documenting GLUT4 exocytosis and endocytosis in muscle cell monolayers. Curr Protoc Cell Biol, Chapter 15: Unit 15.15.
18. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al,. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128. (Pubitemid 39468014)
19. Johnston O, Rose CL, Webster AC, Gill JS, (2008). Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19: 1411-1418.
20. Kenerson HL, Yeh MM, Yeung RS, (2011). Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. PLoS ONE 6: e18075.
21. Kneteman NM, Lakey JR, Wagner T, Finegood D, (1996). The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 61: 1206-1210. (Pubitemid 26134771)
22. Konings IR, Verweij J, Wiemer EA, Sleijfer S, (2009). The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 9: 439-450.
23. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC Jr, (2008). Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol 28: 61-70.
24. Kumar A, Lawrence JC, Jr, Jung DY, Ko HJ, Keller SR, Kim JK, et al,. (2010). Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 59: 1397-1406.
25. Manning BD, (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167: 399-403. (Pubitemid 39489047)
26. Marcelli-Tourvieille S, Hubert T, Moerman E, Gmyr V, Kerr-Conte J, Nunes B, et al,. (2007). In vivo and in vitro effect of sirolimus on insulin secretion. Transplantation 83: 532-538. (Pubitemid 46440238)
27. Menon S, Manning BD, (2008). Common corruption of the mTOR signaling network in human tumors. Oncogene 27 (Suppl. 2): S43-S51.
28. Mitsumoto Y, Klip A, (1992). Development regulation of the subcellular distribution and glycosylation of GLUT1 and GLUT4 glucose transporters during myogenesis of L6 muscle cells. J Biol Chem 267: 4957-4962.
29. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, et al,. (2002). Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43: 1170-1180. (Pubitemid 34988165)
30. Niu W, Huang C, Nawaz Z, Levy M, Somwar R, Li D, et al,. (2003). Maturation of the regulation of GLUT4 activity by p38 MAPK during L6 cell myogenesis. J Biol Chem 278: 17953-17962. (Pubitemid 36799402)
31. Polak P, Hall MN, (2009). mTOR and the control of whole body metabolism. Curr Opin Cell Biol 21: 209-218.
32. Polak P, Cybulski N, Feige JN, Auwerx J, Ruegg MA, Hall MN, (2008). Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 8: 399-410.
33. Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, et al,. (2007). Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 131: 476-491. (Pubitemid 350017761)
34. Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, et al,. (2006). Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 38: 1034-1036. (Pubitemid 43815926)
35. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al,. (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
36. Stallone G, Infante B, Grandaliano G, Gesualdo L, (2009). Management of side effects of sirolimus therapy. Transplantation 87 (8 Suppl.): S23-S26.
37. Taha C, Mitsumoto Y, Liu Z, Skolnik EY, Klip A, (1995). The insulin-dependent biosynthesis of GLUT1 and GLUT3 glucose transporters in L6 muscle cells is mediated by distinct pathways. Roles of p21ras and pp70 S6 kinase. J Biol Chem 270: 24678-24681.
38. Taha C, Liu Z, Jin J, Al-Hasani H, Sonenberg N, Klip A, (1999). Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem 274: 33085-33091. (Pubitemid 129535350)
39. Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B, (1986). Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats. Endocrinology 118: 674-678. (Pubitemid 16162788)
40. Teutonico A, Schena PF, Di Paolo S, (2005). Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16: 3128-3135. (Pubitemid 44743511)
41. Thirone AC, Huang C, Klip A, (2006). Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab 17: 72-78.
42. Tremblay F, Brule S, Hee Um S, Li Y, Masuda K, Roden M, et al,. (2007). Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 104: 14056-14061. (Pubitemid 350003334)
43. Tsang CK, Qi H, Liu LF, Zheng XF, (2007). Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12: 112-124. (Pubitemid 46176669)
44. Tzatsos A, Kandror KV, (2006). Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63-76.
45. Um SH, D'Alessio D, Thomas G, (2006). Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 3: 393-402. (Pubitemid 43811780)
46. Vettor R, Zarjevski N, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B, (1994). Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 37: 1202-1208. (Pubitemid 24356759)
47. Veyrat-Durebex C, Montet X, Vinciguerra M, Gjinovci A, Meda P, Foti M, et al,. (2009). The Lou/C rat: a model of spontaneous food restriction associated with improved insulin sensitivity and decreased lipid storage in adipose tissue. Am J Physiol Endocrinol Metab 296: E1120-E1132.
48. Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F, Foti M, (2008). PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 134: 268-280. (Pubitemid 350309315)
49. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M, (2009). Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 49: 1176-1184.
50. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR, et al,. (1999). Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol 19: 4008-4018. (Pubitemid 29241975)
51. Whiting PH, Woo J, Adam BJ, Hasan NU, Davidson RJ, Thomson AW, (1991). Toxicity of rapamycin-a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat. Transplantation 52: 203-208.
52. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN, (1994). Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17: 30-36.
53. Wood IS, Trayhurn P, (2003). Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 89: 3-9. (Pubitemid 36187532)
54. Wredenberg A, Freyer C, Sandstrom ME, Katz A, Wibom R, Westerblad H, et al,. (2006). Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance. Biochem Biophys Res Commun 350: 202-207. (Pubitemid 44466593)
55. Wullschleger S, Loewith R, Hall MN, (2006). TOR signaling in growth and metabolism. Cell 124: 471-484. (Pubitemid 43199434)
56. Zaid H, Antonescu CN, Randhawa VK, Klip A, (2008). Insulin action on glucose transporters through molecular switches, tracks and tethers. Biochem J 413: 201-215.
57. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, et al,. (2006). Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 55: 2429-2436. (Pubitemid 44871142)